The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.

IFN-beta, a type I IFN, is widely used for the treatment of MS. However, the mechanisms behind its therapeutic efficacy are not well understood. Using a murine model of MS, EAE, we demonstrate that the Th17-mediated development of autoimmune disease is constrained by Toll-IL-1 receptor domain-containing adaptor inducing IFN-beta-dependent (TRIF-dependent) type I IFN production and its downstream signaling pathway. Mice with defects in TRIF or type I IFN receptor (IFNAR) developed more severe EAE. Notably, these mice exhibited marked CNS inflammation, as manifested by increased IL-17 production. In addition, IFNAR-dependent signaling events were essential for negatively regulating Th17 development. Finally, IFN-beta-mediated IL-27 production by innate immune cells was critical for the immunoregulatory role of IFN-beta in the CNS autoimmune disease. Together, our findings not only may provide a molecular mechanism for the clinical benefits of IFN-beta in MS but also demonstrate a regulatory role for type I IFN induction and its downstream signaling pathways in limiting Th17 development and autoimmune inflammation.

[1]  D. Littman,et al.  Transcriptional regulation of Th17 cell differentiation. , 2007, Seminars in immunology.

[2]  H. Weiner,et al.  A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells , 2007, Nature Immunology.

[3]  Mohamed El-behi,et al.  Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27–stimulated T cells , 2007, Nature Immunology.

[4]  Christopher A Hunter,et al.  Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10 , 2007, Nature Immunology.

[5]  D. Fitzgerald,et al.  Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis1 , 2007, The Journal of Immunology.

[6]  D. Levy,et al.  IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways , 2007, Nature Immunology.

[7]  A. D. Panopoulos,et al.  Essential autocrine regulation by IL-21 in the generation of inflammatory T cells , 2007, Nature.

[8]  Terry B. Strom,et al.  IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells , 2007, Nature.

[9]  M. Goldman,et al.  IL-27 Synthesis Induced by TLR Ligation Critically Depends on IFN Regulatory Factor 31 , 2007, The Journal of Immunology.

[10]  A. Tourbah,et al.  Interferons in multiple sclerosis: ten years' experience. , 2007, Biochimie.

[11]  Genhong Cheng,et al.  Cutting Edge: Involvement of the Type I IFN Production and Signaling Pathway in Lipopolysaccharide-Induced IL-10 Production1 , 2007, The Journal of Immunology.

[12]  R. Nussenblatt,et al.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 , 2007, Nature Medicine.

[13]  Y. Wan,et al.  T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. , 2007, Immunity.

[14]  M. McGeachy,et al.  T Cells Doing It for Themselves: TGF-β Regulation of Th1 and Th17 Cells , 2007 .

[15]  Taba K. Amouzegar,et al.  Synergistic interaction between Toll-like receptor agonists is required for induction of experimental autoimmune encephalomyelitis in Lewis rats , 2007, Journal of Neuroimmunology.

[16]  L. Hennighausen,et al.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.

[17]  R. D. Hatton,et al.  IL-17 family cytokines and the expanding diversity of effector T cell lineages. , 2007, Annual review of immunology.

[18]  R. Kastelein,et al.  Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. , 2007, Annual review of immunology.

[19]  M. Buttmann,et al.  Interferon-β1b in multiple sclerosis , 2007, Expert review of neurotherapeutics.

[20]  J. Leonard,et al.  IL-23 Is Critical in the Induction but Not in the Effector Phase of Experimental Autoimmune Encephalomyelitis , 2007, The Journal of Immunology.

[21]  Lawrence Steinman,et al.  A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2007, Nature Medicine.

[22]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[23]  Xiaojing Ma,et al.  Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-γ–mediated pathways , 2007, The Journal of experimental medicine.

[24]  T. Mcclanahan,et al.  IL-25 regulates Th17 function in autoimmune inflammation , 2007, The Journal of experimental medicine.

[25]  J. Lohr,et al.  Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease , 2006, The Journal of experimental medicine.

[26]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[27]  R. Medzhitov,et al.  Type I interferons in host defense. , 2006, Immunity.

[28]  L. Hennighausen,et al.  Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system , 2006, Nature Immunology.

[29]  J. Colgan,et al.  All in the family: IL-27 suppression of TH-17 cells , 2006, Nature Immunology.

[30]  B. Becher,et al.  Interleukin 18–independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation , 2006, Nature Immunology.

[31]  D. Danilenko,et al.  Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17–producing T cells , 2006, Nature Immunology.

[32]  K. Mills,et al.  A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.

[33]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[34]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[35]  C. Dong.  Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells , 2006, Nature Reviews Immunology.

[36]  James A. Thomas,et al.  Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity , 2006, Journal of Neuroimmunology.

[37]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[38]  B. Becher,et al.  Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. , 2006, The Journal of clinical investigation.

[39]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[40]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[41]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[42]  J. Antel,et al.  TLR Signaling Tailors Innate Immune Responses in Human Microglia and Astrocytes1 , 2005, The Journal of Immunology.

[43]  C. Hunter.  New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions , 2005, Nature Reviews Immunology.

[44]  M. Kamoun,et al.  IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis , 2005, Journal of the Neurological Sciences.

[45]  A. Suzumura,et al.  Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations , 2005, Brain Research.

[46]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[47]  R. Kastelein,et al.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.

[48]  Soojin Lee,et al.  Toll-like receptors and inflammation in the CNS. , 2002, Current drug targets. Inflammation and allergy.

[49]  Roland Martin,et al.  The immunopathogenesis of multiple sclerosis. , 2002, Journal of rehabilitation research and development.

[50]  J. Orange,et al.  Interferon-α/β inhibition of interleukin 12 and interferon-γ production in vitro and endogenously during viral infection , 1997 .

[51]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.

[52]  M. McGeachy,et al.  T cells doing it for themselves: TGF-beta regulation of Th1 and Th17 cells. , 2007, Immunity.

[53]  A. Cabral,et al.  Autoimmune inflammation from the Th17 perspective. , 2007, Autoimmunity reviews.

[54]  T. Wynn.  T(H)-17: a giant step from T(H)1 and T(H)2. , 2005, Nature immunology.

[55]  C. Le Page,et al.  Interferon activation and innate immunity. , 2000, Reviews in immunogenetics.

[56]  J. Orange,et al.  Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.